---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107268"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:37:05.530587+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma Q2 net loss $8.5M; BI deal with $12M upfront, $345M milestones

## Summary
- Net loss $8.5M ($0.09/share) vs $10.2M in Q2 2024; collaboration revenue $3.0M.
- Announced collaboration with Boehringer Ingelheim for CUE-501: $12M upfront, up to $345M milestones.
- Received FDA Pre-IND feedback supporting CUE-401 IND for autoimmune disease.
- CUE-101 Phase 1 data: 50% ORR, 88% 12-mo OS, median OS 32 months in HPV+ HNSCC.
- Raised ~$20M via public offering; cash position $27.5M at June 30.

## SEC filing metadata
- accession: 0000950170-25-107268
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095017025107268/0000950170-25-107268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095017025107268/cue-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107268
- JSON: https://secwatch.observer/filing/0000950170-25-107268.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107268.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.